KDR and cancer: Here, we tested ramucirumab or the anti-mouse VEGFR2 antibody DC101 (a ramucirumab surrogate for in vivo studies) in multiple pediatric cancer cell lines and xenograft mouse models with the goal of identifying specific pediatric indications that may respond to ramucirumab-mediated VEGFR2 inhibition.